Uncategorized

PHARMA/QUALITY: Merrill Goozner has dug into “The Most Costly Earmark in S-CHIP”

GoozNews: The Most Costly Earmark in S-CHIP

Increased risk of death. No benefit. Higher costs for taxpayers. The ongoing Epo saga, whose latest chapter is being written on Capitol Hill, is a perfect example of why our health care outcomes are second-rate, while our health care costs are second to none.

This is a great bit of digging from Merrill, and it shows why FFS or in this case, Fee for drugs is just a bad way of paying for medical care. Do read it.

Livongo’s Post Ad Banner 728*90

Categories: Uncategorized

Tagged as: , ,

1
Leave a Reply

1 Comment threads
0 Thread replies
0 Followers
 
Most reacted comment
Hottest comment thread
1 Comment authors
Zach Shoup Recent comment authors
newest oldest most voted
Zach Shoup
Guest

This is infuriating, but a seemingly typical example of public health policy in today’s America. My great-grandmother recently started dialysis through the ESRD program and I will certainly be making sure that my grandparents who help manage her health know to ask her physician about this drug.